Mogrify (Cell Mogrify Ltd) is a private biotechnology company has developed a direct cellular conversion technology to allow for the transformation (transmogrification) of any mature human cell type into any other – without going through a pluripotent stem cell- or progenitor cell-state. [Read more…]
There has been tremendous activity over the last decade in the development of stem cells therapeutics, which have relied on stem cell differentiation protocols, as well as techniques for direct cell reprogramming. Today, there are over 4,700 stem cell trials registered on ClinicalTrials.gov and publications have increased dramatically in recent years, demonstrating the rapidly growing interest of the scientific community.
However, for all its promise, stem cells are yet to deliver on this therapeutic potential, and this failure appears due to various technical challenges that still need to be overcome. [Read more…]
What do we know of the safety and efficacy of stem cell therapeutics? Over 50 years have passed since the discovery of hematopoietic stem cells (bone marrow transplantation to cure diseases such as leukemia), almost 20 years since the discovery of human embryonic stem cells (hESC), and 10 years since the discovery of induced pluripotent stem cells (iPS cells). There are also more than 5,000 stem cell trials ongoing in clinics globally. Despite this experience, what do we actually know about the safety and efficacy of stem cell therapeutics?
Stem Cell Therapeutics and Safe Practice
In this article:
Safety and Efficacy Issues with Stem Cell Therapies
In this novel and increasingly complex stem cell space, it is perhaps a timely question to ask, especially since the regulatory assessment criteria designed for conventional medicines are not directly applicable for stem cell therapy. [Read more…]